Galectin Therapeutics (GALT) Tops Q1 EPS by 2c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Worthington Enterprises raises dividend 5%, adds board member